[go: up one dir, main page]

WO2000060062A3 - Human signal transduction serine/threonine protein kinase - Google Patents

Human signal transduction serine/threonine protein kinase Download PDF

Info

Publication number
WO2000060062A3
WO2000060062A3 PCT/GB2000/001183 GB0001183W WO0060062A3 WO 2000060062 A3 WO2000060062 A3 WO 2000060062A3 GB 0001183 W GB0001183 W GB 0001183W WO 0060062 A3 WO0060062 A3 WO 0060062A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
signal transduction
threonine protein
well
human signal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/001183
Other languages
French (fr)
Other versions
WO2000060062A2 (en
Inventor
Tyrrell Errick Norris
William Craig Moore
David Shay Silberstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to AU35662/00A priority Critical patent/AU3566200A/en
Publication of WO2000060062A2 publication Critical patent/WO2000060062A2/en
Publication of WO2000060062A3 publication Critical patent/WO2000060062A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

An isolated and purified human signal transduction serine threonine protein kinase is described. A cDNA sequence which encodes the native signal transduction polypeptide is disclosed as well as the structural coding region and the amino acid residue sequence of the protein kinase. Methods are provided which employ the novel sequences to identify compounds that modulate the biological and/or pharmacological activity of the signal transduction protein kinase and hence regulate cellular and tissue physiology. Biologically-effective antisense molecules, as well as dominant negative mutant versions of the protein kinase, are described which are suitable for therapeutic use. The invention is also related to the diagnosis, study, prevention, and treatment of pathophysiological disorders related to or mediated by the signal transduction molecule.
PCT/GB2000/001183 1999-04-01 2000-03-28 Human signal transduction serine/threonine protein kinase Ceased WO2000060062A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35662/00A AU3566200A (en) 1999-04-01 2000-03-28 Human signal transduction serine/threonine protein kinase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28395699A 1999-04-01 1999-04-01
US09/283,956 1999-04-01

Publications (2)

Publication Number Publication Date
WO2000060062A2 WO2000060062A2 (en) 2000-10-12
WO2000060062A3 true WO2000060062A3 (en) 2001-01-18

Family

ID=23088302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001183 Ceased WO2000060062A2 (en) 1999-04-01 2000-03-28 Human signal transduction serine/threonine protein kinase

Country Status (2)

Country Link
AU (1) AU3566200A (en)
WO (1) WO2000060062A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049118B2 (en) 2001-01-03 2006-05-23 Bayer Healthcare Ag Regulation of human serine-threonine protein kinase
WO2003033708A2 (en) * 2001-10-15 2003-04-24 Bayer Healthcare Ag Regulation of human serine/threonine protein kinase
CA2464729A1 (en) * 2001-10-30 2003-05-08 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7482134B2 (en) 2002-06-05 2009-01-27 Seoul National University Industry Foundation Signals and molecular species involved in senescence
DE60319093T2 (en) 2002-08-06 2009-02-05 Sanofi-Aventis Deutschland Gmbh METHOD OF ISOLATING AN INTESTILANE CHOLESTERIN BIND PROTEIN
EP1498133A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma Deutschland GmbH Use of a pak inhibitor for the treatment of a joint disease
US7364887B2 (en) 2003-07-18 2008-04-29 Sanofi-Aventis Deutschland Gmbh Use of PAK inhibitor for the treatment of a joint disease
US7998688B2 (en) 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053036A2 (en) * 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053036A2 (en) * 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ABO A. ET AL.: "PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia", THE EMBO JOURNAL, vol. 17, no. 22, November 1998 (1998-11-01), pages 6527 - 6540, XP002147782 *
BAGRODIA S. ET AL.: "Pak to the future", TRENDS IN CELL BIOLOGY, vol. 9, no. 9, September 1999 (1999-09-01), pages 350 - 355, XP000925936 *
HILLIER L. ET AL.: "The WashU-Merck EST Project; yf64a05.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:26963 3', mRNA sequence", EMBL DATABASE ENTRY HS772102; ACCESSION NO. R37772, 4 May 1995 (1995-05-04), XP002147781 *
HILLIER L. ET AL.: "The WashU-Merck EST Project; ym92f08.r1 Soares adult brain N2b4HB55Y Homo sapiens cDNA clone IMAGE:166407 5', mRNA sequence", EMBL DATABASE ENTRY HS460188; ACCESSION NO. R88460, 24 August 1995 (1995-08-24), XP002147780 *
NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XV. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO", DNA RESEARCH, vol. 6, no. 5, 29 October 1999 (1999-10-29), pages 337 - 345, XP000865804, ISSN: 1340-2838 *
OHARA O. ET AL.: "Homo sapiens mRNA for KIAA1264 protein, partial cds.", EMBL DATABASE ENTRY AB033090; ACCESSION NO. AB033090, XP002147972 *
ROE B.A.: "Homo sapiens Chromosome 22q11.2 PAC Clone p201m18 In DGCR Region; complete sequence", EMBL DATABASE ENTRY HSAC97; ACCESSION NO. AC000097, 7 December 1996 (1996-12-07), XP002147852 *
WILLIAM S.: "Human DNA sequence from clone RP1-80N2 on chromosome 6p24.1-25.3. Contains the gene for MD-1, part of a putative novel gene, ESTs,STSs, GSSs and three putative GpG islands.", EMBL DATABASE ENTRY HS80N2; ACCESSION NO. AL031123, 24 July 1998 (1998-07-24), XP002147853 *

Also Published As

Publication number Publication date
AU3566200A (en) 2000-10-23
WO2000060062A2 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
AU4278299A (en) Human receptor tyrosine kinase
US8058242B2 (en) Chimeric proteins with natriuretic activity
US10487113B2 (en) Peptide having activity to improve skin condition and use thereof
Thweatt et al. A novel gene encoding a smooth muscle protein is overexpressed in senescent human fibroblasts
CN107921085B (en) Methods and compositions for treating aging-related disorders
KR101813629B1 (en) Peptides Having Activities of Skin Condition Improvement and Uses Thereof
PT813545E (en) Nucleotide and protein sequences of vertebrate serrate genes and methods based thereon
WO2004076478A1 (en) PEPTIDE DERIVATIVES HAVING β-SECRETASE INHIBITORY ACTIVITY
WO2000047618A3 (en) HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
AU684968B2 (en) Human interleukin 6 inhibitor
WO2000060062A3 (en) Human signal transduction serine/threonine protein kinase
AU7610396A (en) Connective tissue growth factor-3
AU7477201A (en) Inhibitory pas domain protein (ipas) and screening methods related to angiogenesis and tumor progression
AU2642795A (en) Transforming growth factor alpha hii
WO2005035716A3 (en) Nucleic acid molecules encoding novel human low-voltage activated calcium channel proteins, designated - alpha 1i-1 and alpha 1i-2, encoded proteins and methods of use thereof
ATE410516T1 (en) VARIANTS OF HUMAN GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE D AND THEIR USES
EP4032901A1 (en) Recombinant human neuregulin derivatives and use thereof
WO2008077938A1 (en) Modulators of talin/integrin association and use thereof
CN113853382A (en) Novel peptides and their uses
HK40081680A (en) Recombinant human neuregulin derivatives and use thereof
WO2001030366A3 (en) Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases
SE0002417D0 (en) Promote sequences
EP1640359A3 (en) Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
JP2006282574A (en) Acoustic trauma therapeutic agent using cell death inhibitory activity-enhancing protein FNK
WO2002046420A3 (en) Nebulin-related protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP